The genetics of haemostasis: a twin study

[1]  J. Weisel,et al.  The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. , 2000, Blood.

[2]  T. Spector,et al.  Twins. Novel uses to study complex traits and genetic diseases. , 2000, Trends in genetics : TIG.

[3]  P. Grant,et al.  Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. , 2000, Blood.

[4]  M Farrall,et al.  Genetic influences on F cells and other hematologic variables: a twin heritability study. , 2000, Blood.

[5]  P. Grant,et al.  Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking, and hypertension. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[6]  D. Lillicrap,et al.  Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF :Ag levels : Identification of three novel single nucleotide polymorphisms in the vWF gene promoter , 1999 .

[7]  P. Grant,et al.  FXII (46C→T) Polymorphism and In Vivo Generation of FXII Activity , 1999, Thrombosis and Haemostasis.

[8]  Yuling Hong,et al.  Genetic Effects for Plasma Factor VII Levels Independent of and in Common with Triglycerides , 1999, Thrombosis and Haemostasis.

[9]  S. Vettore,et al.  Determinants of plasma levels of plasminogen activator inhibitor-1 : A study of normotensive twins. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[10]  P. Grant,et al.  A Common Coding Polymorphism in the FXIII A-subunit Gene (FXIIIVAL34LEU) Affects Cross-linking Activity , 1998, Thrombosis and Haemostasis.

[11]  M. Laffan,et al.  Analysis of the F8 Gene in Individuals with High Plasma Factor VIII:C Levels and Associated Venous Thrombosis , 1998, Thrombosis and Haemostasis.

[12]  G. Siest,et al.  Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[13]  P. Elwood,et al.  Fibrin D-dimer, Tissue Plasminogen Activator, Plasminogen Activator Inhibitor, and the Risk of Major Ischaemic Heart Disease in the Caerphilly Study , 1998, Thrombosis and Haemostasis.

[14]  A. Carter,et al.  Levels of Activated FXII in Survivors of Myocardial Infarction – Association with Circulating Risk Factors and Extent of Coronary Artery Disease , 1998, Thrombosis and Haemostasis.

[15]  U. de Faire,et al.  Moderate genetic influences on plasma levels of plasminogen activator inhibitor-1 and evidence of genetic and environmental influences shared by plasminogen activator inhibitor-1, triglycerides, and body mass index. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[16]  J. Barrett,et al.  von Willebrand Factor and Factor VIII: C in Acute Cerebrovascular Disease , 1997, Thrombosis and Haemostasis.

[17]  D. Arveiler,et al.  Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[18]  D. Ginsburg,et al.  Von Willebrand disease. , 2008, Pediatric clinics of North America.

[19]  N. Ossei-Gerning,et al.  Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[20]  M. Pinotti,et al.  Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[21]  S. Humphries,et al.  The 4G/5G Genetic Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Is Associated with Differences in Plasma PAI-1 Activity but not with Risk of Myocardial Infarction in the ECTIM Study , 1995, Thrombosis and Haemostasis.

[22]  Y. Friedlander,et al.  Genetic and environmental sources of fibrinogen variability in Israeli families: the Kibbutzim Family Study. , 1995, American journal of human genetics.

[23]  L. Berkman,et al.  Genetic susceptibility to death from coronary heart disease in a study of twins. , 1994, The New England journal of medicine.

[24]  P. Ridker,et al.  Endogenous tissue-type plasminogen activator and risk of myocardial infarction , 1993, The Lancet.

[25]  D. Barker,et al.  Relation of fetal and infant growth to plasma fibrinogen and factor VII concentrations in adult life. , 1992, BMJ.

[26]  W. Kannel,et al.  Coronary risk associated with age and sex of parental heart disease in the Framingham Study. , 1989, The American journal of cardiology.

[27]  M. Blombäck,et al.  GENETIC AND CULTURAL INHERITANCE OF PLASMA FIBRINOGEN CONCENTRATION , 1987, The Lancet.

[28]  R. D'Agostino,et al.  Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.

[29]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[30]  S. Thompson,et al.  HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.

[31]  P. Magnus,et al.  Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. , 1985, American journal of human genetics.

[32]  A. Bloom Haemostasis and thrombosis , 1981 .

[33]  H. Clink,et al.  Letter: Quality and quantity of survival in acute myeloid leukaemia. , 1975, Lancet.

[34]  Oxon Dm Obituary. Rupert Samuel Bruce Pearson. , 1974 .

[35]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .